Core Insights - Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for Effexor® SR (venlafaxine hydrochloride) as the first and only treatment option for adults with generalized anxiety disorder (GAD) in Japan, addressing a significant unmet medical need [1][2] - The approval is based on a Phase 3 clinical trial that demonstrated the superiority of Effexor® in reducing anxiety symptoms compared to placebo, achieving its primary objective at 8 weeks [2][4] - GAD affects approximately 7.6% of the general population in Japan, indicating a substantial market opportunity for Viatris [2][3] Company Strategy - The approval of Effexor® reflects Viatris' strategy to advance a differentiated and innovative portfolio in Japan, focusing on value-added therapies [2][4] - The company aims to leverage its strong infrastructure and expertise in central nervous system therapies to enhance patient access to this new treatment [2][4] Clinical Study Details - The Phase 3 study (Study B2411367) was a placebo-controlled, randomized, double-blind, multicenter trial that met all primary and secondary efficacy endpoints [2][4] - Effexor® was well tolerated, with low discontinuation rates due to treatment-emergent adverse events (TEAEs) [4] Market Context - GAD is a prevalent mental health condition that significantly impacts quality of life, with a lifetime prevalence of 2.6% in Japan according to the World Health Organization [3] - The introduction of Effexor® is expected to address the underdiagnosis of GAD in Japan, providing a much-needed treatment option [3]

Core Insights - Viatris Inc. reported strong third-quarter 2025 financial results, reflecting solid operational execution and strategic focus on growth initiatives [2][6][14] - The company updated its full-year financial guidance, raising and narrowing ranges for total revenues, adjusted EBITDA, and adjusted EPS, primarily due to foreign exchange impacts and share repurchases [2][18][19] Financial Performance - Total revenues for Q3 2025 were $3.76 billion, flat year-over-year, with a slight operational decline of 1% after adjusting for divestitures [4][14] - Net sales in developed markets decreased by 2%, while emerging markets saw a 7% increase, driven by strong performance in Greater China [4][14] - U.S. GAAP net loss for Q3 2025 was $(128.2) million, compared to net earnings of $94.8 million in Q3 2024, with diluted EPS at $(0.11) [4][14][37] Capital Allocation - The company returned over $920 million to shareholders year-to-date, including $500 million in share repurchases, and remains on track to exceed $1 billion in total capital returns in 2025 [2][12][14] - Free cash flow for Q3 2025 was $658 million, impacted by $70 million in transaction-related costs [5][14] Strategic Initiatives - Viatris is advancing its pipeline with key regulatory submissions, including a New Drug Application for a low-dose estrogen weekly patch and the acquisition of Aculys Pharma, enhancing its portfolio in Japan [2][14][11] - The company is conducting an enterprise-wide strategic review to identify operational efficiencies and reinvest savings into growth opportunities [14][16][17] Market Outlook - The company anticipates continued growth in emerging markets and specific developed markets, with a focus on launching new products and enhancing its operational capabilities [2][14][33] - Viatris plans to hold an Investor Event in Q1 2026 to provide updates on its strategic and financial outlook, including pipeline developments [17]